Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study.

Siderowf A, Jennings D, Eberly S, Oakes D, Hawkins KA, Ascherio A, Stern MB, Marek K; PARS Investigators.

Mov Disord. 2012 Mar;27(3):406-12. doi: 10.1002/mds.24892. Epub 2012 Jan 11.

PMID:
22237833
2.

Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study.

Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, Marek K; PARS Investigators.

Neurology. 2014 Nov 4;83(19):1739-46. doi: 10.1212/WNL.0000000000000960. Epub 2014 Oct 8.

3.

Nonmotor symptoms in LRRK2 G2019S associated Parkinson's disease.

Gaig C, Vilas D, Infante J, Sierra M, García-Gorostiaga I, Buongiorno M, Ezquerra M, Martí MJ, Valldeoriola F, Aguilar M, Calopa M, Hernandez-Vara J, Tolosa E.

PLoS One. 2014 Oct 17;9(10):e108982. doi: 10.1371/journal.pone.0108982. eCollection 2014.

4.

Parkinson disease and sleep: sleep-wake changes in the premotor stage of Parkinson disease; impaired olfaction and other prodromal features.

Iranzo A.

Curr Neurol Neurosci Rep. 2013 Sep;13(9):373. doi: 10.1007/s11910-013-0373-0. Review.

PMID:
23881622
5.

Prevalence and timeline of nonmotor symptoms in idiopathic rapid eye movement sleep behavior disorder.

Aguirre-Mardones C, Iranzo A, Vilas D, Serradell M, Gaig C, Santamaría J, Tolosa E.

J Neurol. 2015 Jun;262(6):1568-78. doi: 10.1007/s00415-015-7742-3. Epub 2015 May 1.

PMID:
25929658
6.

The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study).

Pont-Sunyer C, Hotter A, Gaig C, Seppi K, Compta Y, Katzenschlager R, Mas N, Hofeneder D, Brücke T, Bayés A, Wenzel K, Infante J, Zach H, Pirker W, Posada IJ, Álvarez R, Ispierto L, De Fàbregues O, Callén A, Palasí A, Aguilar M, Martí MJ, Valldeoriola F, Salamero M, Poewe W, Tolosa E.

Mov Disord. 2015 Feb;30(2):229-37. doi: 10.1002/mds.26077. Epub 2014 Dec 1.

PMID:
25449044
7.

Selective hyposmia in Parkinson disease: association with hippocampal dopamine activity.

Bohnen NI, Gedela S, Herath P, Constantine GM, Moore RY.

Neurosci Lett. 2008 Dec 5;447(1):12-6. doi: 10.1016/j.neulet.2008.09.070. Epub 2008 Sep 30.

8.

Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease.

Bohnen NI, Gedela S, Kuwabara H, Constantine GM, Mathis CA, Studenski SA, Moore RY.

J Neurol. 2007 Jan;254(1):84-90. Epub 2007 Feb 14.

PMID:
17508142
9.

Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease.

Ponsen MM, Stoffers D, Wolters ECh, Booij J, Berendse HW.

J Neurol Neurosurg Psychiatry. 2010 Apr;81(4):396-9. doi: 10.1136/jnnp.2009.183715. Epub 2009 Dec 3.

PMID:
19965851
11.

[Olfactory dysfunction in Parkinson disease and REM sleep behavior disorder].

Miyamoto T.

Brain Nerve. 2012 Apr;64(4):356-63. Review. Japanese.

PMID:
22481508
12.

Risk factors for Parkinson's disease and impaired olfaction in relatives of patients with Parkinson's disease.

Siderowf A, Jennings D, Connolly J, Doty RL, Marek K, Stern MB.

Mov Disord. 2007 Nov 15;22(15):2249-55.

PMID:
17876851
13.

Risk factors and prodromal markers and the development of Parkinson's disease.

Lerche S, Seppi K, Behnke S, Liepelt-Scarfone I, Godau J, Mahlknecht P, Gaenslen A, Brockmann K, Srulijes K, Huber H, Wurster I, Stockner H, Kiechl S, Willeit J, Gasperi A, Fassbender K, Poewe W, Berg D.

J Neurol. 2014 Jan;261(1):180-7. doi: 10.1007/s00415-013-7171-0. Epub 2013 Nov 5.

PMID:
24190794
14.

Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease.

Morley JF, Weintraub D, Mamikonyan E, Moberg PJ, Siderowf AD, Duda JE.

Mov Disord. 2011 Sep;26(11):2051-7. doi: 10.1002/mds.23792. Epub 2011 May 24.

15.

Potential sex differences in nonmotor symptoms in early drug-naive Parkinson disease.

Liu R, Umbach DM, Peddada SD, Xu Z, Tröster AI, Huang X, Chen H.

Neurology. 2015 May 26;84(21):2107-15. doi: 10.1212/WNL.0000000000001609. Epub 2015 Apr 29.

16.

Olfactory dysfunction in LRRK2 G2019S mutation carriers.

Saunders-Pullman R, Stanley K, Wang C, San Luciano M, Shanker V, Hunt A, Severt L, Raymond D, Ozelius LJ, Lipton RB, Bressman SB.

Neurology. 2011 Jul 26;77(4):319-24. doi: 10.1212/WNL.0b013e318227041c. Epub 2011 Jul 13.

17.

Olfactory dysfunction in Parkinson disease.

Doty RL.

Nat Rev Neurol. 2012 May 15;8(6):329-39. doi: 10.1038/nrneurol.2012.80. Review.

PMID:
22584158
18.

Prodromal features for Parkinson's disease--baseline data from the TREND study.

Gaenslen A, Wurster I, Brockmann K, Huber H, Godau J, Faust B, Lerche S, Eschweiler GW, Maetzler W, Berg D.

Eur J Neurol. 2014 May;21(5):766-72. doi: 10.1111/ene.12382. Epub 2014 Feb 24.

PMID:
24612314
19.

Motor and non-motor correlates of olfactory dysfunction in Parkinson's disease.

Berendse HW, Roos DS, Raijmakers P, Doty RL.

J Neurol Sci. 2011 Nov 15;310(1-2):21-4. doi: 10.1016/j.jns.2011.06.020. Epub 2011 Jun 25.

PMID:
21705022
20.

Evaluation of progression markers in the premotor phase of Parkinson's disease: the progression markers in the premotor phase study.

Liepelt-Scarfone I, Gauss K, Maetzler W, Müller K, Bormann C, Fruhmann Berger M, Timmers M, Streffer J, Berg D.

Neuroepidemiology. 2013;41(3-4):174-82. doi: 10.1159/000353560. Epub 2013 Sep 17.

Items per page

Supplemental Content

Write to the Help Desk